Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Leukemia|April 9, 2004
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)C-M Wendtner, M Ritgen, C D Schweighofer, et al.
Leukemia|June 11, 2016
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemiaH Parker, M J J Rose-Zerilli, M Larrayoz, et al.
Leukemia|April 18, 2006
Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expressionM Bilban, D Heintel, T Scharl, et al.
Leukemia|April 29, 2005
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemiaD Heintel, D Kienle, M Shehata, et al.
Leukemia|November 25, 2005
The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemiaS Skogsberg, G Tobin, A Kröber, et al.
Leukemia|February 3, 2012
ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemiaS Pospisilova, D Gonzalez, J Malcikova, et al.
Leukemia|August 15, 2017
Lamin B1 regulates somatic mutations and progression of B-cell malignanciesT Klymenko, J Bloehdorn, J Bahlo, et al.
Leukemia|May 3, 2016
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLLC Maurer, P Langerbeins, J Bahlo, et al.
Leukemia|October 25, 2016
Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemiaG Lohmann, E Vasyutina, J Bloehdorn, et al.
Blood Cancer Journal|March 12, 2016
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trialA Bühler, C-M Wendtner, T J Kipps, et al.
Pageof 9